摘要：SummaryTargeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by restoring antitumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Neuropilin-1 (NRP1) is a transmembrane glycoprotein required for nervous system and angiogenesis embryonic development, also expressed in immune cells. We hypothesized that NRP1 could be an immune checkpoint co-receptor modulating CD8+T cells activity in the context of the antitumor immune response. Here, we show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+T cells, cooperates and enhances PD-1 activity. In mice, CD8+T cells specific deletion ofNrp1improves anti-PD1 antibody antitumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+T cells predicts poor outcome of patients treated with anti-PD1. NRP1 is a promising target to overcome resistance to anti-PD1 therapies.Graphical abstractDisplay OmittedHighlights•NRP1 modulates PD1 activity secondary to complexes formation on CD8+T cells•Anti-PD1 therapy is synergistic with NRP1 specific deletion on CD8+T cells in mouse•NRP1 expression on CD8+TILs predicts poor outcome in patients treated with anti-PD1Immunology ; Cancer;
